ReviewPharmaceuticals (Basel, Switzerland)2024
Neuroprotective Potential of Glycyrrhizic Acid in Ischemic Stroke: Mechanisms and Therapeutic Prospects.
Review in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- A Novel Hyaluronic Acid-Glycyrrhizic Acid Complex Mitigates γ-Radiation-Induced Neurotransmitter Damage in Rats.Applied biochemistry and biotechnology · 2026Article
- Small extracellular vesicle-integrated by herbal hydrogels for spatiotemporal immunomodulation and neurovascular repair following traumatic brain injury.Bioactive materials · 2026Article
- Multitarget Actions of Pentacyclic Triterpenic Acids in Alzheimer's Disease: Mechanistic Insights.Molecules (Basel, Switzerland) · 2026Review
- Mechanisms and therapeutic potential of glycyrrhizic acid: Insights into key signaling pathways and disease modulation (Review).Molecular medicine reports · 2026Review
- Glycyrrhizic Acid Attenuates AβCells · 2026Article
- Ameliorative effect of glycyrrhizin in mitochondrial drug-resistant epilepsy: role of HMGB1 inhibition.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Novel Glycyrrhizinic Acid Derivative YCY-20 Inhibits Cerebral Ischemia/Reperfusion Induced Apoptosis via the AGE-RAGE/MAPK Pathway.CNS neuroscience & therapeutics · 2026Article
- Monoammonium glycyrrhizinate ameliorates mitochondrial dysfunction-mediated oxidative stress and neuroinflammation via the NRF2/NQO1 axis after spinal cord injury.Redox report : communications in free radical research · 2025Article
- Targeting the NLRP3 inflammasome with natural products for ischemia-reperfusion injury across organs: mechanisms, structure-activity relationships, and delivery innovations.Inflammopharmacology · 2025Review
- Medicine-food homology bioactives in Parkinson's disease: multi-target oxidative-stress modulation and translation to dietary supplements.Frontiers in nutrition · 2025Review
- Neuroprotective synergy of curcumin andFrontiers in pharmacology · 2025Article
- Dynamic mechanisms and targeted interventions in cerebral ischemia-reperfusion injury: pathological cascade from ischemia to reperfusion and promising therapeutic strategies.Frontiers in neuroscience · 2025Review
- Traditional, complementary, and integrative medicine in the management of ischemic stroke: a narrative review.Frontiers in pharmacology · 2025Review
- Anti-DAMP therapies for acute inflammation.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.